Company: DVAX
Filing Date: 2025-10-16
Form Type: 8-K
Source: 0001193125-25-240766
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-10-16
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with an internal realignment of various management roles and responsibilities, on October 15, 2025, the Board of Directors (the “ Board”) of Dynavax Technologies Corporation (the “ Company”) approved the transition of David F. Novack from his roles as the Company’s President and Chief Operating Officer to his new roles as Senior Vice President and Chief Operating Officer, effective January 1, 2026. The Board also approved the removal of Robert Janssen, M. D.’s roles as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, effective upon the earlier to occur of (a) the date the Company employs a new Chief Medical Officer and (b) March 2, 2026, and further approved the conclusion of Dr. Janssen’s employment as of March 2, 2026.

The Company has commenced a search process for a successor Chief Medical Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                                       Dynavax Technologies Corporation        
  Date: October 15, 2025      By:      /s/ John Slebir                         
                                       John Slebir